S&P 500   3,114.46 (-0.18%)
DOW   27,860.83 (-0.26%)
QQQ   202.89 (-0.24%)
CGC   17.42 (+13.71%)
BABA   182.96 (-1.24%)
GE   11.44 (-0.52%)
T   36.63 (-3.61%)
ACB   2.64 (+12.82%)
F   8.78 (-1.35%)
BAC   32.76 (-0.55%)
DIS   147.68 (-0.47%)
S&P 500   3,114.46 (-0.18%)
DOW   27,860.83 (-0.26%)
QQQ   202.89 (-0.24%)
CGC   17.42 (+13.71%)
BABA   182.96 (-1.24%)
GE   11.44 (-0.52%)
T   36.63 (-3.61%)
ACB   2.64 (+12.82%)
F   8.78 (-1.35%)
BAC   32.76 (-0.55%)
DIS   147.68 (-0.47%)
S&P 500   3,114.46 (-0.18%)
DOW   27,860.83 (-0.26%)
QQQ   202.89 (-0.24%)
CGC   17.42 (+13.71%)
BABA   182.96 (-1.24%)
GE   11.44 (-0.52%)
T   36.63 (-3.61%)
ACB   2.64 (+12.82%)
F   8.78 (-1.35%)
BAC   32.76 (-0.55%)
DIS   147.68 (-0.47%)
S&P 500   3,114.46 (-0.18%)
DOW   27,860.83 (-0.26%)
QQQ   202.89 (-0.24%)
CGC   17.42 (+13.71%)
BABA   182.96 (-1.24%)
GE   11.44 (-0.52%)
T   36.63 (-3.61%)
ACB   2.64 (+12.82%)
F   8.78 (-1.35%)
BAC   32.76 (-0.55%)
DIS   147.68 (-0.47%)
Log in

Sierra Oncology News Headlines (NASDAQ:SRRA)

$0.24
-0.01 (-4.00 %)
(As of 11/20/2019 08:54 AM ET)
Today's Range
$0.23
Now: $0.24
$0.25
50-Day Range
$0.24
MA: $0.31
$0.39
52-Week Range
$0.23
Now: $0.24
$2.01
Volume358,500 shs
Average Volume675,687 shs
Market Capitalization$17.93 million
P/E RatioN/A
Dividend YieldN/A
Beta1.25

Headlines

Sierra Oncology (NASDAQ SRRA) News Headlines

Source:
DateHeadline
Sierra Oncology +10% premarket on launching late-stage Momentum trialSierra Oncology +10% premarket on launching late-stage Momentum trial
seekingalpha.com - November 20 at 12:16 PM
Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with MyelofibrosisSierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis
finance.yahoo.com - November 20 at 7:16 AM
Sierra Oncology to Present at the Jefferies 2019 London Healthcare ConferenceSierra Oncology to Present at the Jefferies 2019 London Healthcare Conference
finance.yahoo.com - November 14 at 4:30 PM
Short Interest in Sierra Oncology Inc (NASDAQ:SRRA) Grows By 18.6%Short Interest in Sierra Oncology Inc (NASDAQ:SRRA) Grows By 18.6%
www.americanbankingnews.com - November 14 at 11:28 AM
Zacks: Analysts Expect Sierra Oncology Inc (NASDAQ:SRRA) Will Post Earnings of -$0.20 Per ShareZacks: Analysts Expect Sierra Oncology Inc (NASDAQ:SRRA) Will Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - November 11 at 5:32 AM
FY2019 EPS Estimates for Sierra Oncology Inc (NASDAQ:SRRA) Boosted by WedbushFY2019 EPS Estimates for Sierra Oncology Inc (NASDAQ:SRRA) Boosted by Wedbush
www.americanbankingnews.com - November 8 at 8:46 AM
BRIEF-Sierra Oncology And Gilead Sciences Agree On Amendments To Asset Purchase Agreement For MomelotinibBRIEF-Sierra Oncology And Gilead Sciences Agree On Amendments To Asset Purchase Agreement For Momelotinib
www.msn.com - November 7 at 11:02 PM
BRIEF-Sierra Oncology Announces Pricing Of $103 Mln Public Offering Of Convertible Preferred Stock And WarrantsBRIEF-Sierra Oncology Announces Pricing Of $103 Mln Public Offering Of Convertible Preferred Stock And Warrants
www.msn.com - November 7 at 11:02 PM
Sierra Oncology down 19% after pricing equity offeringSierra Oncology down 19% after pricing equity offering
seekingalpha.com - November 7 at 1:00 PM
Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and WarrantsSierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants
finance.yahoo.com - November 7 at 1:00 PM
Sierra Oncology and Gilead Sciences Agree on Amendments to Asset Purchase Agreement for MomelotinibSierra Oncology and Gilead Sciences Agree on Amendments to Asset Purchase Agreement for Momelotinib
finance.yahoo.com - November 7 at 1:00 PM
Sierra Oncology readies equity offering; shares down 21% after hoursSierra Oncology readies equity offering; shares down 21% after hours
seekingalpha.com - November 6 at 7:38 PM
Sierra Oncology Announces Proposed Public Offering of Convertible Preferred Stock and WarrantsSierra Oncology Announces Proposed Public Offering of Convertible Preferred Stock and Warrants
finance.yahoo.com - November 6 at 7:38 PM
Sierra Oncology to Report New Analyses Supporting Momelotinibs Anemia Benefits at ASH 2019Sierra Oncology to Report New Analyses Supporting Momelotinib's Anemia Benefits at ASH 2019
finance.yahoo.com - November 6 at 9:37 AM
Sierra Oncology (NASDAQ:SRRA) Issues Quarterly  Earnings ResultsSierra Oncology (NASDAQ:SRRA) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 5 at 8:44 AM
Sierra Oncology EPS beats by $0.04Sierra Oncology EPS beats by $0.04
seekingalpha.com - November 4 at 7:32 PM
Sierra Oncology Reports Third Quarter 2019 ResultsSierra Oncology Reports Third Quarter 2019 Results
finance.yahoo.com - November 4 at 7:32 PM
Short Interest in Sierra Oncology Inc (NASDAQ:SRRA) Decreases By 8.5%Short Interest in Sierra Oncology Inc (NASDAQ:SRRA) Decreases By 8.5%
www.americanbankingnews.com - October 31 at 1:19 PM
Sierra Oncology Inc.Sierra Oncology Inc.
www.barrons.com - October 11 at 11:42 PM
Do Institutions Own Shares In Sierra Oncology, Inc. (NASDAQ:SRRA)?Do Institutions Own Shares In Sierra Oncology, Inc. (NASDAQ:SRRA)?
finance.yahoo.com - September 14 at 7:58 AM
Sierra Oncology Reports Second Quarter 2019 ResultsSierra Oncology Reports Second Quarter 2019 Results
finance.yahoo.com - August 8 at 7:49 PM
Did Sierra Oncology, Inc. (NASDAQ:SRRA) Insiders Buy Up More Shares?Did Sierra Oncology, Inc. (NASDAQ:SRRA) Insiders Buy Up More Shares?
finance.yahoo.com - July 15 at 6:04 PM
Hedge Funds Have Never Been More Bullish On Sierra Oncology, Inc. (SRRA)Hedge Funds Have Never Been More Bullish On Sierra Oncology, Inc. (SRRA)
finance.yahoo.com - June 30 at 8:56 AM
Sierra Oncology to focus resources on lead drug momelotinibSierra Oncology to focus resources on lead drug momelotinib
seekingalpha.com - June 27 at 6:01 PM
FDA grants Fast Track designation to Sierras momelotinibFDA grants Fast Track designation to Sierra's momelotinib
seekingalpha.com - June 5 at 8:54 AM
Sierra Announces Momelotinib Granted FDA Fast Track DesignationSierra Announces Momelotinib Granted FDA Fast Track Designation
finance.yahoo.com - June 5 at 8:54 AM
Sierra Announces FDA Regulatory Clarity for Momelotinib & Design of the MOMENTUM Phase 3 Clinical TrialSierra Announces FDA Regulatory Clarity for Momelotinib & Design of the MOMENTUM Phase 3 Clinical Trial
finance.yahoo.com - June 4 at 6:13 PM
Sierra Holds Analyst & Investor Event for SRA737Sierra Holds Analyst & Investor Event for SRA737
finance.yahoo.com - June 3 at 9:02 AM
Sierra Announces Promising Preliminary Efficacy in SRA737 Clinical Program & Outlines Potential Path to RegistrationSierra Announces Promising Preliminary Efficacy in SRA737 Clinical Program & Outlines Potential Path to Registration
finance.yahoo.com - June 1 at 9:08 AM
Sierra Oncology to Present Momelotinib and SRA737 Overview at the Jefferies Global Healthcare Conference in New YorkSierra Oncology to Present Momelotinib and SRA737 Overview at the Jefferies Global Healthcare Conference in New York
finance.yahoo.com - May 28 at 9:02 AM
Sierra to Present SRA737 Preliminary Clinical Data and Potential Next Steps at ASCOSierra to Present SRA737 Preliminary Clinical Data and Potential Next Steps at ASCO
finance.yahoo.com - May 15 at 7:38 PM
Sierra Oncology beats by $0.04Sierra Oncology beats by $0.04
seekingalpha.com - May 8 at 9:05 AM
Prep for Sierra placingPrep for Sierra placing
www.lse.co.uk - May 6 at 7:03 PM
Sierra Oncology to Attend Two Investor Conferences in MaySierra Oncology to Attend Two Investor Conferences in May
finance.yahoo.com - May 6 at 9:07 AM
Imagine Owning Sierra Oncology (NASDAQ:SRRA) And Trying To Stomach The 72% Share Price DropImagine Owning Sierra Oncology (NASDAQ:SRRA) And Trying To Stomach The 72% Share Price Drop
finance.yahoo.com - April 26 at 6:25 PM
Health Tech Aim to Change the Way Cancer is TreatedHealth Tech Aim to Change the Way Cancer is Treated
www.prnewswire.com - April 9 at 9:30 AM
Sierra Reports Late-Breaking SRA141 Preclinical Data in Poster at AACR 2019Sierra Reports Late-Breaking SRA141 Preclinical Data in Poster at AACR 2019
finance.yahoo.com - April 3 at 10:14 AM
Sierra Reports Late-Breaking Preclinical Data for SRA737 Presented at AACR 2019Sierra Reports Late-Breaking Preclinical Data for SRA737 Presented at AACR 2019
finance.yahoo.com - April 1 at 7:05 PM
Sierra Oncology to Present at the Cowen 39th Annual Health Care Conference in BostonSierra Oncology to Present at the Cowen 39th Annual Health Care Conference in Boston
finance.yahoo.com - March 5 at 9:32 AM
Sierra Oncology Reports 2018 Year End ResultsSierra Oncology Reports 2018 Year End Results
finance.yahoo.com - February 28 at 9:12 AM
Sierra Oncology Announces Late-Breaking Oral and Poster Presentations at AACR 2019 for SRA737 and SRA141 Preclinical DataSierra Oncology Announces Late-Breaking Oral and Poster Presentations at AACR 2019 for SRA737 and SRA141 Preclinical Data
finance.yahoo.com - February 27 at 6:34 PM
Do Institutions Own Sierra Oncology, Inc. (NASDAQ:SRRA) Shares?Do Institutions Own Sierra Oncology, Inc. (NASDAQ:SRRA) Shares?
finance.yahoo.com - January 22 at 5:49 PM
Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with MomelotinibSierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
finance.yahoo.com - December 3 at 9:03 AM
Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
finance.yahoo.com - November 29 at 5:05 PM
Sierra Oncology to Host Analyst Call Highlighting Clinical Data on Momelotinibs Anemia BenefitSierra Oncology to Host Analyst Call Highlighting Clinical Data on Momelotinib's Anemia Benefit
finance.yahoo.com - November 28 at 9:15 AM
How Does Sierra Oncology Inc (NASDAQ:SRRA) Affect Your Portfolio Volatility?How Does Sierra Oncology Inc (NASDAQ:SRRA) Affect Your Portfolio Volatility?
finance.yahoo.com - November 22 at 4:55 PM
Sierra Oncology Reports Preclinical Efficacy for Chk1 inhibitor SRA737 in Treatment Refractory Ovarian Cancer Models at the EORTC-NCI-AACR SymposiumSierra Oncology Reports Preclinical Efficacy for Chk1 inhibitor SRA737 in Treatment Refractory Ovarian Cancer Models at the EORTC-NCI-AACR Symposium
finance.yahoo.com - November 15 at 8:56 AM
Sierra Oncology Reports SRA141 Preclinical Efficacy at EORTC-NCI-AACR SymposiumSierra Oncology Reports SRA141 Preclinical Efficacy at EORTC-NCI-AACR Symposium
finance.yahoo.com - November 13 at 8:45 AM
SIERRA ONCOLOGY, INC.SIERRA ONCOLOGY, INC.
www.streetinsider.com - November 10 at 8:59 AM
Sierra Oncology to Present at the Jefferies 2018 London Healthcare ConferenceSierra Oncology to Present at the Jefferies 2018 London Healthcare Conference
finance.yahoo.com - November 7 at 9:06 AM
This page was last updated on 11/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel